Now available for 21 genes
Fetal Focus™, the next-generation single-gene NIPT
Powered by ultra-sensitive LinkedSNP™ technology.
Backed by robust validation in the prospective EXPAND clinical trial.
Introducing the next-generation single-gene NIPT
WEBINAR
How to streamline comprehensive prenatal genetic testing with Fetal Focus™
September 8, 2026 | 12 PM PT / 3 PM ET
September 9, 2026 | 9 AM PT / 12 PM ET
30 Minute Webinar
Upcoming Webinar
Join Natera’s Medical Director Dr. Amber Shamburger, who has over 15 years of clinical experience, as she shares her approach to discussing prenatal genetic testing with patients now that sgNIPTs can inform next steps after carrier findings.
Natera Medical Science Liaison Matt Herbst will highlight Natera’s latest tools and services that help clinicians integrate Fetal Focus™ sgNIPT into their workflow.
Direct fetal risk assessment for 21 recessive and X-linked genes
By directly screening the fetus for inherited single-gene conditions using cfDNA, Fetal Focus™ addresses challenges with standard carrier screening when the partner does not complete testing. The test screens for ACOG-recommended conditions like cystic fibrosis and sickle cell disease,1 and now includes up to 21 autosomal recessive and X-linked genes.
Early Interventions for Conditions Screened by Fetal Focus™
FDA-approved
interventional treatments
- Cystic fibrosis (CFTR)
- Spinal muscular atrophy (SMN1)
- Alpha-thalassemia (HBA1/2)
- Beta-hemoglobinopathies including sickle cell disease (HBB)
- Duchenne muscular dystrophy (DMD)*
- Glycogen storage disease Type 2 (Pompe disease) (GAA)
- Krabbe disease (GALC)
- Gaucher disease (GBA)
Dietary modifications
or supplements
- Medium-chain acyl-CoA dehydrogenase deficiency (ACADM)
- Phenylketonuria (PAH)
- Smith-Lemli-Opitz syndrome (DHCR7)
- Carnitine palmitoyltransferase II deficiency (CPT2)
- Galactosemia (GALT)
- Familial mediterranean fever (MEFV)
Management that reduces
complications or supports development
- Canavan disease (ASPA)
- Tay-Sachs disease (HEXA)
- Familial dysautonomia (IKBKAP)
- Fragile X (FMR1)*
- Polycystic kidney disease, autosomal recessive (PKHD1)
- Wilson disease (ATP7B)
*Fetal risk assessment for X-linked conditions is based on fetal sex only. Fetal Focus™ does not directly screen the fetal DMD or FMR1 genes
Proven performance presented in the oral plenary session at SMFM
…these latest results strengthen the evidence base needed for responsible integration of single-gene NIPT into clinical practice.
Powered by ultra-sensitive LinkedSNP™ technology
Fetal Focus™ combines direct variant detection with our ultra-sensitive LinkedSNP™ technology to assess if the fetal variant was inherited from the mother or father. This innovation enables improved detection of affected pregnancies across diverse populations.
Designed to integrate into your workflow with ease
Comprehensive fetal insights in one maternal blood draw
Add Fetal Focus™ to the #1 ordered Panorama™ NIPT and Horizon™ carrier screen in one workflow4
Learn more about the next‑generation Fetal Focus™ sgNIPT
1American College of Obstetricians and Gynecologists, Committee Opinion #691, March 2017
2Internal EXPAND validation data. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results. 12/294 samples did not receive a result.
3Expanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). https://clinicaltrials.gov/study/NCT06808880.Accessed December 2025.
4Internal analysis of Denitive Healthcare database and ancillary data. Dec 2023.